Arcutis logo.png
Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream
December 13, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
Data presented at Revolutionizing Atopic Dermatitis (RAD) ConferenceVehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from...
Arcutis logo.png
Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021 16:02 ET | Arcutis Biotherapeutics, Inc.
Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of diseaseInitiated single pivotal Phase 3 trial of roflumilast foam in scalp...
Arcutis logo.png
Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
October 04, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
Plaque psoriasis is a skin disease that affects approximately 8.6 million individuals in the U.S. and presents particular treatment challenges in certain anatomical regions.Roflumilast cream, a...
Arcutis logo.png
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
September 28, 2021 16:05 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis logo.png
New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress
September 27, 2021 08:05 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Keith-Leonard
Arcutis Announces Appointment of Keith Leonard to Board of Directors
September 02, 2021 16:10 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
Arcutis logo.png
Bruce Binkowitz Joins Arcutis as Vice President of Biometrics
August 23, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
Arcutis logo.png
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 16:05 ET | Arcutis Biotherapeutics, Inc.
Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of...
Arcutis logo.png
Arcutis Announces Additions to its Investor Relations and Communications Team
August 02, 2021 16:05 ET | Arcutis Biotherapeutics, Inc.
Eric McIntyre joins as Head of Investor RelationsAmanda Sheldon joins as Head of Corporate Communications WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics,...
Arcutis logo.png
Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis
July 21, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
The majority of patients with psoriasis have mild or moderate levels of diseaseThe new method, PASI-high discrimination (PASI-HD), is designed for use in clinical trials evaluating novel topical...